May 11, 2026 4:05 pm EDT Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Apr 02, 2026 5:00 am EDT Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Feb 06, 2026 7:00 am EST Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Jan 23, 2026 5:25 pm EST Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Nov 10, 2025 7:00 am EST Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025
Oct 27, 2025 4:10 pm EDT Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Sep 03, 2025 12:57 pm EDT Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Aug 11, 2025 7:00 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025
May 29, 2025 7:00 am EDT Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025